Clinical trials: Severe Respiratory Distress
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Respiratory Distress Syndrome, Ventilator-Induced Lung Injury
Impact of the Depth of Neuromuscular Blockade on Respiratory Mechanics in Moderate to Severe ARDS Patients
Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory…
- Trial name
- NCT05697666
- Testing
- Modulation of the depth of the neuromuscular blockade
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier de Saint-Brieuc
Fluid Responsiveness
Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness
In the critically ill population, fluid administration in an unstable patient is perhaps the most common intervention that is performed.
- Trial name
- PHOENIX (NCT06390423)
- Testing
- Passive leg raise, SVI via bioreactance, Echo based VTI
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- CentraCare
Severe Acute Respiratory Syndrome Coronavirus 2, Electric Impedance
Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients
The consensus therapeutic strategy implies that COVID patients with acute lung injury due to coronavirus are routinely placed in prone position in an attempt to improve oxygenation by increasing ventilation homogeneity.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Electric Impedance, Prone Positioning
- Trial name
- COVID-19_EIT (NCT04359407)
- Testing
- Prone positioning
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Walid HABRE
High-flow Nasal Cannula, Respiratory Distress
The Factors Causing Treatment Failure in Children Receiving Oxygen Therapy With High-flow Nasal Cannula
The goal of this observational study is to identify the variables that predict treatment failure in order to identify the patients in which HFNC treatment may fail and not delay the transition to advanced respiratory support…
- Conditions
- High-flow Nasal Cannula, Respiratory Distress, Treatment Failure
- Trial name
- NCT06146439
- Where
- Turkey (Türkiye)
- Volunteers
- 201 people
- Sponsor
- Dr. Behcet Uz Children's Hospital
Severe Sepsis, Acute Respiratory Distress Syndrome
Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)
This study aims to test the effectiveness of a single intravenous (IV, through the vein) dose of the study drug, bevacizumab (Avastin), in preventing/reducing the development of Acute Respiratory Distress Syndrome (ARDS), in…
- Trial name
- VEGF-ARDS (NCT01314066)
- Testing
- Bevacizumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Respiratory Distress Syndrome, Positive-Pressure Respiration
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability
This observational study will explore the effects of PEEP and position on regional lung ventilation-perfusion mismatch by electrical impedance tomography (EIT) in moderate-to-severe ARDS patients with different lung…
- Conditions
- Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation
- Trial name
- NCT06430554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
ARDS (Moderate or Severe)
Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome
The goal of this clinical trial is to evaluate whether inhaled nitric oxide (iNO), added to standard care, can reduce mortality in adults with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- ENARCT-ARDS (NCT07334873)
- Testing
- Inhaled Nitric Oxide Therapy
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Nanfang Hospital, Southern Medical University
COVID-19 Pneumonia, Thrombosis
Practice Variation on Antithrombotics in COVID-19
Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations.
- Conditions
- COVID-19 Pneumonia, Thrombosis, COVID-19 Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Trial name
- NCT04998799
- Testing
- Current clinical practices of participating physicians
- Where
- India
- Volunteers
- 435 people
- Sponsor
- NMC Specialty Hospital
Acue Respiratory Distress Syndrome
Use of Extracorporeal CO2 Removal in Case of Moderate to Severe ARDS to Apply an Ultraprotective Mechanical Ventilation Strategy
The extracorporeal CO2 removal (ECCO2R) has been recently proposed in case of Acute Respiratory Distress Syndrome (ARDS) in order to reduce pulmonary injuries induced by the mechanical ventilation.
- Trial name
- ECCO2R (NCT04556578)
- Testing
- High-flow extracorporeal CO2 removal
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Montpellier
COVID, Corona Virus Infection
RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease.
- Conditions
- COVID, Corona Virus Infection, Acute Lung Injury, Ischemia Limb
- Trial name
- NCT04659460
- Testing
- Remote Ischemic Conditioning
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
COVID-19
In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection
To estimate the pulmonary response microvascular thrombosis in critical patients due to SARS-Cov-2., at the Hospital General de México "Dr.
- Trial name
- NCT04926428
- Testing
- tPA
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Grupo Mexicano para el Estudio de la Medicina Intensiva
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
ARDS (Acute Respiratory Distress Syndrome)
Pressure Release Ventilation Compared to Lung Protective Ventilation in Moderate and Severe ARDS
This study compares two different ways of providing mechanical ventilation to patients with moderate to severe acute respiratory distress syndrome (ARDS), a serious condition in which the lungs become inflamed and make it…
- Trial name
- NCT07803614
- Testing
- Arm 1 Intervention Name: Low-Tidal-Volume Ventilation (LTV)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Koot Ahmad
Acute Respiratory Distress Syndrome, ARDS
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
This is a quality improvement study with the purpose of observing and measuring the effects of implementation of a proven standardized lung protective ventilation protocol in the new electronic medical record system iCentra…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency
- Trial name
- IMPROVENT (NCT03225807)
- Where
- United States
- Volunteers
- 8,692 people
- Sponsor
- Intermountain Health Care, Inc.
Sepsis, Delirium
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in…
- Conditions
- Sepsis, Delirium, Impaired Cognition
- Trial name
- MENDS2 (NCT01739933)
- Testing
- Dexmedetomidine, Propofol
- Where
- 11 sites in United States
- Volunteers
- 438 people
- Sponsor
- Vanderbilt University Medical Center